The plaintiffs claim that Qiagen's QIAseq kits infringe Archer's US Patent No. 10,017,810, which covers parts of its Anchored Multiplex PCR (AMP) technology.
The researchers plan to use ArcherDX's technology to evaluate minimal residual disease in pediatric AML patients participating in a clinical trial.
Ambry will offer ArcherDX's immune repertoire sequencing assays to biopharmaceutical customers.
The company intends to use the funds to support the commercial growth of its targeted sequencing assays.
The companion diagnostic will leverage ArcherDx's Anchored Multiplex PCR technology, Illumina's MiSdqDx sequencer, and Archer Analysis bioinformatics software.
The firm has inked a number of significant deals over the past year and presented research involving new assays at last week's American Molecular Pathology meeting.
In PLOS this week: transcription levels linked to uracil mutations, transcriptomic analysis of medicinal leech, and more.
An Associated Press poll finds that most US adults say they'd want to know whether they carried a gene variant predisposing them to an incurable disease.
Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.
Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.